Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles

Alan Ivan Green, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R21DA044501 (GREEN, ALAN I) Sep 1, 2017 - Aug 31, 2019
    NIH/NIDA
    Reward circuit dysfunction, substance use disorder and schizophrenia: a preclinical fMRI-based connectivity study
    Role: Principal Investigator
  2. KL2TR001088 (GREEN, ALAN I) Sep 26, 2013 - Apr 30, 2018
    NIH/NCATS
    SYNERGY: The Dartmouth Center for clinical and Translational Science
    Role: Principal Investigator
  3. UL1TR001086 (GREEN, ALAN I) Sep 26, 2013 - Apr 30, 2018
    NIH/NCATS
    SYNERGY: The Dartmouth Center for clinical and Translational Science
    Role: Principal Investigator
  4. R01DA034699 (GREEN, ALAN I) Sep 15, 2013 - Mar 31, 2020
    NIH/NIDA
    Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
    Role: Principal Investigator
  5. R01DA032533 (GREEN, ALAN I) Jul 15, 2012 - Dec 31, 2017
    NIH/NIDA
    Clozapine for Cannabis Use Disorder in Schizophrenia
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Doucette WT, Dwiel L, Boyce JE, Simon AA, Khokhar JY, Green AI. Machine Learning Based Classification of Deep Brain Stimulation Outcomes in a Rat Model of Binge Eating Using Ventral Striatal Oscillations. Front Psychiatry. 2018; 9:336. PMID: 30123143.
    View in: PubMed
  2. Brown ES, Green AI. Tobacco Use, Medical Illness, and Service Utilization. J Dual Diagn. 2018 Jan-Mar; 14(1):1. PMID: 29166211.
    View in: PubMed
  3. Khokhar JY, Henricks AM, Sullivan EDK, Green AI. Unique Effects of Clozapine: A Pharmacological Perspective. Adv Pharmacol. 2018; 82:137-162. PMID: 29413518.
    View in: PubMed
  4. Brown ES, Green AI. Hispanic Populations, Veterans, and Symptom Assessment. J Dual Diagn. 2017 Oct-Dec; 13(4):237. PMID: 29166212.
    View in: PubMed
  5. Green AI, Khokhar JY. Addiction and schizophrenia: A translational perspective. Schizophr Res. 2018 Apr; 194:1-3. PMID: 29046253.
    View in: PubMed
  6. Eisenberg IW, Bissett PG, Canning JR, Dallery J, Enkavi AZ, Whitfield-Gabrieli S, Gonzalez O, Green AI, Greene MA, Kiernan M, Kim SJ, Li J, Lowe MR, Mazza GL, Metcalf SA, Onken L, Parikh SS, Peters E, Prochaska JJ, Scherer EA, Stoeckel LE, Valente MJ, Wu J, Xie H, MacKinnon DP, Marsch LA, Poldrack RA. Applying novel technologies and methods to inform the ontology of self-regulation. Behav Res Ther. 2018 Feb; 101:46-57. PMID: 29066077.
    View in: PubMed
  7. Whitfield-Gabrieli S, Fischer AS, Henricks AM, Khokhar JY, Roth RM, Brunette MF, Green AI. Understanding marijuana's effects on functional connectivity of the default mode network in patients with schizophrenia and co-occurring cannabis use disorder: A pilot investigation. Schizophr Res. 2018 Apr; 194:70-77. PMID: 28823723.
    View in: PubMed
  8. Brown ES, Green AI. From the Editors: Brief Synopsis. J Dual Diagn. 2017 Jul-Sep; 13(3):167. PMID: 28521661.
    View in: PubMed
  9. Khokhar JY, Dwiel LL, Henricks AM, Doucette WT, Green AI. The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophr Res. 2018 Apr; 194:78-85. PMID: 28416205.
    View in: PubMed
  10. Brown ES, Green AI. Trauma, Case Studies, and Dual Diagnosis Consequences. J Dual Diagn. 2017 Apr-Jun; 13(2):81. PMID: 28494224.
    View in: PubMed
  11. Green AI. Time for a Change. J Dual Diagn. 2016 Jul-Dec; 12(3-4):203. PMID: 27831825.
    View in: PubMed
  12. Brown ES, Green AI. This Issue. J Dual Diagn. 2016 Jul-Dec; 12(3-4):204. PMID: 27831854.
    View in: PubMed
  13. Drake RE, Green AI. Illuminating the Interstices: What Small Studies Add to Science. J Dual Diagn. 2016 Apr-Jun; 12(2):107-8. PMID: 27070957.
    View in: PubMed
  14. Brunette MF, Akerman SC, Dawson R, O'Keefe CD, Green AI. An open-label pilot study of quetiapine plus mirtazapine for heavy drinkers with alcohol use disorder. Alcohol. 2016 06; 53:45-50. PMID: 27256763.
    View in: PubMed
  15. Khokhar JY, Green AI. Effects of iloperidone, combined with desipramine, on alcohol drinking in the Syrian golden hamster. Neuropharmacology. 2016 06; 105:25-34. PMID: 26796639; PMCID: PMC4873404 [Available on 06/01/17].
  16. Drake RE, Green AI. Trauma, Technology, and Routine Outcome Measures. J Dual Diagn. 2016; 12(1):1-3. PMID: 26829002.
    View in: PubMed
  17. Doucette WT, Khokhar JY, Green AI. Nucleus accumbens deep brain stimulation in a rat model of binge eating. Transl Psychiatry. 2015 Dec 15; 5:e695. PMID: 26670280.
    View in: PubMed
  18. Green AI, Brunette MF, Dawson R, Buckley P, Wallace AE, Hafez H, Herz M, Narasimhan M, Noordsy DL, O'Keefe C, Sommi RW, Steinbook RM, Weeks M. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. J Clin Psychiatry. 2015 Oct; 76(10):1359-65. PMID: 26302441.
    View in: PubMed
  19. Chau DT, Khokhar JY, Gulick D, Dawson R, Green AI. Desipramine enhances the ability of paliperidone to decrease alcohol drinking. J Psychiatr Res. 2015 Oct; 69:9-18. PMID: 26343589; PMCID: PMC4561861 [Available on 10/01/16].
  20. Khokhar JY, Chau DT, Dawson R, Green AI. Clozapine reconstructed: Haloperidol's ability to reduce alcohol intake in the Syrian golden hamster can be enhanced through noradrenergic modulation by desipramine and idazoxan. Drug Alcohol Depend. 2015 Jul 01; 152:277-81. PMID: 25979645; PMCID: PMC4458150.
  21. Drake RE, Green AI. Progress in Dual Diagnosis Research: Innovation and Controlled Trials. J Dual Diagn. 2015; 11(3-4):151-2. PMID: 26683250.
    View in: PubMed
  22. Drake RE, Green AI. A call for creativity in dual diagnosis research. J Dual Diagn. 2015; 11(2):93-6. PMID: 25782138.
    View in: PubMed
  23. Green AI, Drake RE. Subtyping and tailoring treatment approaches. J Dual Diagn. 2015; 11(1):1-2. PMID: 25671682.
    View in: PubMed
  24. Akerman SC, Brunette MF, Green AI, Goodman DJ, Blunt HB, Heil SH. Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review. J Subst Abuse Treat. 2015 May; 52:40-7. PMID: 25592332; PMCID: PMC4382443.
  25. Fischer AS, Whitfield-Gabrieli S, Roth RM, Brunette MF, Green AI. Response to "cortico-accumbens circuitry in schizophrenia: merely a reward system?" by Rolland and Jardri (SCHRES-14-D-00731). Schizophr Res. 2015 Feb; 161(2-3):519. PMID: 25465412; PMCID: PMC4785886.
  26. Akerman SC, Brunette MF, Noordsy DL, Green AI. Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders. Curr Addict Rep. 2014 Dec; 1(4):251-260. PMID: 27226947.
    View in: PubMed
  27. Fischer AS, Whitfield-Gabrieli S, Roth RM, Brunette MF, Green AI. Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: Effects of cannabis and THC. Schizophr Res. 2014 Sep; 158(1-3):176-82. PMID: 25037524; PMCID: PMC4778557.
  28. Gulick D, Chau DT, Khokhar JY, Dawson R, Green AI. Desipramine enhances the ability of risperidone to decrease alcohol intake in the Syrian golden hamster. Psychiatry Res. 2014 Aug 30; 218(3):329-34. PMID: 24836200; PMCID: PMC4407141.
  29. Mesholam-Gately RI, Gibson LE, Seidman LJ, Green AI. Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine. Schizophr Res. 2014 May; 155(1-3):45-51. PMID: 24685823.
    View in: PubMed
  30. Drake RE, Green AI. From the editors. J Dual Diagn. 2014; 10(2):59. PMID: 25392247.
    View in: PubMed
  31. Drake RE, Green AI. From the editors. J Dual Diagn. 2014; 10(3):107. PMID: 25392283.
    View in: PubMed
  32. Drake RE, Green AI. Developing innovative interventions for people with dual diagnosis. J Dual Diagn. 2014; 10(4):175-6. PMID: 25391274.
    View in: PubMed
  33. Drake RE, Green AI. New awareness, new populations, new technologies, and new ideas. J Dual Diagn. 2014; 10(1):1-2. PMID: 25392056.
    View in: PubMed
  34. Chau DT, Khokhar JY, Dawson R, Ahmed J, Xie H, Green AI. The comparative effects of clozapine versus haloperidol on initiation and maintenance of alcohol drinking in male alcohol-preferring P rat. Alcohol. 2013 Dec; 47(8):611-8. PMID: 24280363.
    View in: PubMed
  35. Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, Green AI, Pettinati HM, Ciraulo DA, Sarid-Segal O, Kampman K, Brunette MF, Strain EC, Tiouririne NA, Ransom J, Scott C, Stout R. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med. 2013 Jul-Aug; 7(4):277-86. PMID: 23728065; PMCID: PMC3914416.
  36. Gamsby JJ, Templeton EL, Bonvini LA, Wang W, Loros JJ, Dunlap JC, Green AI, Gulick D. The circadian Per1 and Per2 genes influence alcohol intake, reinforcement, and blood alcohol levels. Behav Brain Res. 2013 Jul 15; 249:15-21. PMID: 23608482; PMCID: PMC3672323.
  37. Evins AE, Green AI, Kane JM, Murray RM. Does using marijuana increase the risk for developing schizophrenia? J Clin Psychiatry. 2013 Apr; 74(4):e08. PMID: 23656852.
    View in: PubMed
  38. Fetter JC, Brunette M, Green AI. N-3 fatty acids for hypertriglyceridemia in patients taking second-generation antipsychotics. Clin Schizophr Relat Psychoses. 2013; 7(2):73-77A. PMID: 23367502.
    View in: PubMed
  39. Evins AE, Green AI, Kane JM, Murray RM. The effect of marijuana use on the risk for schizophrenia. J Clin Psychiatry. 2012 Nov; 73(11):1463-8. PMID: 23218162.
    View in: PubMed
  40. Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, Rickman WJ, Scott C, Ciraulo D, Green AI, Tiouririne NA, Johnson B, Pettinati H, Strain EC, Devine E, Brunette MF, Kampman K, A Tompkins D, Stout R. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012 Aug; 36(8):1421-30. PMID: 22324516.
    View in: PubMed
  41. Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NA, Kampman K, Stout R. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012 Mar; 36(3):406-16. PMID: 21950727.
    View in: PubMed
  42. Chau DT, Ahmed J, Wang TT, Xie H, Dawson R, Green AI. Raclopride lessens the ability of clozapine to suppress alcohol drinking in Syrian golden hamsters. Neuropharmacology. 2011 Sep; 61(4):646-52. PMID: 21619888.
    View in: PubMed
  43. Green AI, Drake RE. Current Epidemiology and Emerging Interventions for People With Co-occurring Mental Illness and Substance Use Disorders. J Dual Diagn. 2011; 7(1-2):1-3. PMID: 26954908.
    View in: PubMed
  44. Brunette MF, Dawson R, O'Keefe CD, Narasimhan M, Noordsy DL, Wojcik J, Green AI. A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. J Dual Diagn. 2011; 7(1-2):50-63. PMID: 25914610.
    View in: PubMed
  45. Gulick D, Green AI. Role of caloric homeostasis and reward in alcohol intake in Syrian golden hamsters. Physiol Behav. 2010 Nov 02; 101(4):518-26. PMID: 20688091; PMCID: PMC2957184.
  46. Henderson MB, Green AI, Bradford PS, Chau DT, Roberts DW, Leiter JC. Deep brain stimulation of the nucleus accumbens reduces alcohol intake in alcohol-preferring rats. Neurosurg Focus. 2010 Aug; 29(2):E12. PMID: 20672914.
    View in: PubMed
  47. Chau DT, Gulick D, Xie H, Dawson R, Green AI. Clozapine chronically suppresses alcohol drinking in Syrian golden hamsters. Neuropharmacology. 2010 Feb; 58(2):351-6. PMID: 19895824; PMCID: PMC4427519.
  48. Whitfield-Gabrieli S, Thermenos HW, Milanovic S, Tsuang MT, Faraone SV, McCarley RW, Shenton ME, Green AI, Nieto-Castanon A, LaViolette P, Wojcik J, Gabrieli JD, Seidman LJ. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci U S A. 2009 Jan 27; 106(4):1279-84. PMID: 19164577; PMCID: PMC2633557.
  49. Nasrallah HA, Keshavan MS, Benes FM, Braff DL, Green AI, Gur RE, Kane JM, Perkins DO, Weiden PJ, Weinberger DR, Correll CU. Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia. J Clin Psychiatry. 2009; 70 Suppl 1:4-46. PMID: 19292973.
    View in: PubMed
  50. Wang JF, Min JY, Hampton TG, Amende I, Yan X, Malek S, Abelmann WH, Green AI, Zeind J, Morgan JP. Clozapine-induced myocarditis: role of catecholamines in a murine model. Eur J Pharmacol. 2008 Sep 11; 592(1-3):123-7. PMID: 18627770.
    View in: PubMed
  51. Dawson R, Green AI, Drake RE, McGlashan TH, Schanzer B, Lavori PW. Developing and testing adaptive treatment strategies using substance-induced psychosis as an example. Psychopharmacol Bull. 2008; 41(3):51-67. PMID: 18779776; PMCID: PMC2615414.
  52. Riggs P, Levin F, Green AI, Vocci F. Comorbid psychiatric and substance abuse disorders: recent treatment research. Subst Abus. 2008; 29(3):51-63. PMID: 19042206.
    View in: PubMed
  53. Dunayevich E, Ascher-Svanum H, Zhao F, Jacobson JG, Phillips GA, Dellva MA, Green AI. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychiatry. 2007 Aug; 68(8):1163-71. PMID: 17854239.
    View in: PubMed
  54. Green AI, Noordsy DL, Brunette MF, O'Keefe C. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat. 2008 Jan; 34(1):61-71. PMID: 17574793; PMCID: PMC2930488.
  55. Green AI, Drake RE, Brunette MF, Noordsy DL. Schizophrenia and co-occurring substance use disorder. Am J Psychiatry. 2007 Mar; 164(3):402-8. PMID: 17329463.
    View in: PubMed
  56. Green AI. Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Neurotox Res. 2007 Jan; 11(1):33-40. PMID: 17449446.
    View in: PubMed
  57. Green AI, Brown ES. Comorbid schizophrenia and substance abuse. J Clin Psychiatry. 2006 Sep; 67(9):e08. PMID: 17081075.
    View in: PubMed
  58. Drake RE, Green AI. Current research on co-occurring substance-use disorder in schizophrenia. Schizophr Bull. 2006 Oct; 32(4):616-7. PMID: 16896056; PMCID: PMC2632281.
  59. Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006 Sep; 86(1-3):234-43. PMID: 16887334.
    View in: PubMed
  60. McHugo GJ, Drake RE, Brunette MF, Xie H, Essock SM, Green AI. Enhancing validity in co-occurring disorders treatment research. Schizophr Bull. 2006 Oct; 32(4):655-65. PMID: 16849398; PMCID: PMC2632278.
  61. Brunette MF, Drake RE, Xie H, McHugo GJ, Green AI. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull. 2006 Oct; 32(4):637-43. PMID: 16782758; PMCID: PMC2632279.
  62. Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrhino F, Green AI, Glick IB, Kahn RS, Sharma T, Tohen M, McEvoy JP, Weiden PJ, Lieberman JA. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006 Mar; 83(1):53-63. PMID: 16529910.
    View in: PubMed
  63. Green AI. Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches. J Clin Psychiatry. 2006; 67 Suppl 7:31-5; quiz 36-7. PMID: 16961422.
    View in: PubMed
  64. Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, Strakowski SM, Sharma T, Kahn RS, Gur RE, Tollefson GD, Lieberman JA. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005 Dec; 187:537-43. PMID: 16319406.
    View in: PubMed
  65. Strakowski SM, Johnson JL, Delbello MP, Hamer RM, Green AI, Tohen M, Lieberman JA, Glick I, Patel JK. Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophr Res. 2005 Oct 15; 78(2-3):161-9. PMID: 15950436.
    View in: PubMed
  66. Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, Montoya I, Parks J, Weiss RD. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract. 2005 Sep; 11(5):315-39. PMID: 16184072.
    View in: PubMed
  67. Roth RM, Brunette MF, Green AI. Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism? Curr Psychiatry Rep. 2005 Aug; 7(4):283-91. PMID: 16098282.
    View in: PubMed
  68. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005 Apr; 62(4):361-70. PMID: 15809403.
    View in: PubMed
  69. Niznikiewicz MA, Patel JK, McCarley R, Sutton J, Chau DT, Wojcik J, Green AI. Clozapine action on auditory P3 response in schizophrenia. Schizophr Res. 2005 Jul 01; 76(1):119-21. PMID: 15927806.
    View in: PubMed
  70. Green AI. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. J Clin Psychiatry. 2005; 66 Suppl 6:21-6. PMID: 16107180.
    View in: PubMed
  71. Chau DT, Roth RM, Green AI. The neural circuitry of reward and its relevance to psychiatric disorders. Curr Psychiatry Rep. 2004 Oct; 6(5):391-9. PMID: 15355762.
    View in: PubMed
  72. Green AI, Chau DT, Keung WM, Dawson R, Mesholam RI, Schildkraut JJ. Clozapine reduces alcohol drinking in Syrian golden hamsters. Psychiatry Res. 2004 Aug 30; 128(1):9-20. PMID: 15450910.
    View in: PubMed
  73. Elman I, Rott D, Green AI, Langleben DD, Lukas SE, Goldstein DS, Breier A. Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia. Psychopharmacology (Berl). 2004 Nov; 176(3-4):369-75. PMID: 15179540.
    View in: PubMed
  74. Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004 Feb 01; 66(2-3):125-35. PMID: 15061244.
    View in: PubMed
  75. Le Fauve CE, Litten RZ, Randall CL, Moak DH, Salloum IM, Green AI. Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity. Alcohol Clin Exp Res. 2004 Feb; 28(2):302-12. PMID: 15112938.
    View in: PubMed
  76. Alphs L, Anand R, Islam MZ, Meltzer HY, Kane JM, Krishnan R, Green AI, Potkin S, Chouinard G, Lindenmayer JP, Kerwin R. The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. Schizophr Bull. 2004; 30(3):577-86. PMID: 15631247.
    View in: PubMed
  77. Noordsy DL, Green AI. Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Curr Psychiatry Rep. 2003 Oct; 5(5):340-6. PMID: 13678553.
    View in: PubMed
  78. Drake RE, Green AI, Mueser KT, Goldman HH. The history of community mental health treatment and rehabilitation for persons with severe mental illness. Community Ment Health J. 2003 Oct; 39(5):427-40. PMID: 14635985.
    View in: PubMed
  79. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003 Aug; 160(8):1396-404. PMID: 12900300.
    View in: PubMed
  80. Stone WS, Seidman LJ, Wojcik JD, Green AI. Glucose effects on cognition in schizophrenia. Schizophr Res. 2003 Jul 01; 62(1-2):93-103. PMID: 12765749.
    View in: PubMed
  81. Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res. 2003 Mar 01; 60(1):81-5. PMID: 12505141.
    View in: PubMed
  82. Green AI, Canuso CM, Brenner MJ, Wojcik JD. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am. 2003 Mar; 26(1):115-39. PMID: 12683263.
    View in: PubMed
  83. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003 Jan; 60(1):82-91. PMID: 12511175.
    View in: PubMed
  84. Canuso CM, Goldstein JM, Wojcik J, Dawson R, Brandman D, Klibanski A, Schildkraut JJ, Green AI. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res. 2002 Aug 05; 111(1):11-20. PMID: 12140115.
    View in: PubMed
  85. Elman I, Goldstein DS, Green AI, Eisenhofer G, Folio CJ, Holmes CS, Pickar D, Breier A. Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: a comparison with clozapine and placebo. Neuropsychopharmacology. 2002 Aug; 27(2):293-300. PMID: 12093603.
    View in: PubMed
  86. Green AI, Salomon MS, Brenner MJ, Rawlins K. Treatment of schizophrenia and comorbid substance use disorder. Curr Drug Targets CNS Neurol Disord. 2002 Apr; 1(2):129-39. PMID: 12769622.
    View in: PubMed
  87. Stone WS, Faraone SV, Seidman LJ, Green AI, Wojcik JD, Tsuang MT. Concurrent validation of schizotaxia: a pilot study. Biol Psychiatry. 2001 Sep 15; 50(6):434-40. PMID: 11566160.
    View in: PubMed
  88. Faraone SV, Green AI, Seidman LJ, Tsuang MT. "Schizotaxia": clinical implications and new directions for research. Schizophr Bull. 2001; 27(1):1-18. PMID: 11215539.
    View in: PubMed
  89. Green AI. What is the relationship between schizophrenia and substance abuse? Harv Ment Health Lett. 2000 Oct; 17(4):8. PMID: 11015759.
    View in: PubMed
  90. Green AI, Patel JK, Goisman RM, Allison DB, Blackburn G. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry. 2000 Jul-Aug; 22(4):224-35. PMID: 10936629.
    View in: PubMed
  91. Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman I, Chang H, Zarate C, Posener J, Lee H, Dawson R, Richards C, Cole JO, Schatzberg AF. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry. 2000 Jun; 157(6):982-6. PMID: 10831480.
    View in: PubMed
  92. Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AI. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol. 2000 Feb; 20(1):94-8. PMID: 10653215.
    View in: PubMed
  93. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000; 26(2):441-9. PMID: 10885642.
    View in: PubMed
  94. Strous RD, Patel JK, Zimmet S, Green AI. Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features. Am J Psychiatry. 1999 Jun; 156(6):973-4. PMID: 10360153.
    View in: PubMed
  95. Tsuang MT, Stone WS, Seidman LJ, Faraone SV, Zimmet S, Wojcik J, Kelleher JP, Green AI. Treatment of nonpsychotic relatives of patients with schizophrenia: four case studies. Biol Psychiatry. 1999 Jun 01; 45(11):1412-8. PMID: 10356622.
    View in: PubMed
  96. Green AI, Zimmet SV, Strous RD, Schildkraut JJ. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry. 1999 Mar-Apr; 6(6):287-96. PMID: 10370435.
    View in: PubMed
  97. Canuso CM, Hanau M, Jhamb KK, Green AI. Olanzapine use in women with antipsychotic-induced hyperprolactinemia. Am J Psychiatry. 1998 Oct; 155(10):1458. PMID: 9766782.
    View in: PubMed
  98. Berman I, Merson A, Viegner B, Losonczy MF, Pappas D, Green AI. Obsessions and compulsions as a distinct cluster of symptoms in schizophrenia: a neuropsychological study. J Nerv Ment Dis. 1998 Mar; 186(3):150-6. PMID: 9521350.
    View in: PubMed
  99. Canuso CM, Goldstein JM, Green AI. The evaluation of women with schizophrenia. Psychopharmacol Bull. 1998; 34(3):271-7. PMID: 9803753.
    View in: PubMed
  100. Patel JK, Green AI, Kalinowski A, Tsuang MT. Evaluation of a complex case: the value of a drug washout period. Am J Psychiatry. 1997 Dec; 154(12):1747-50. PMID: 9396956.
    View in: PubMed
  101. Kando JC, Shepski JC, Satterlee W, Patel JK, Reams SG, Green AI. Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia. Ann Pharmacother. 1997 Nov; 31(11):1325-34. PMID: 9391688.
    View in: PubMed
  102. Berman I, Viegner B, Merson A, Allan E, Pappas D, Green AI. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophr Res. 1997 May 03; 25(1):1-10. PMID: 9176922.
    View in: PubMed
  103. Lyons MJ, Toomey R, Meyer JM, Green AI, Eisen SA, Goldberg J, True WR, Tsuang MT. How do genes influence marijuana use? The role of subjective effects. Addiction. 1997 Apr; 92(4):409-17. PMID: 9177062.
    View in: PubMed
  104. Patel JK, Salzman C, Green AI, Tsuang MT. Chronic schizophrenia: response to clozapine, risperidone, and paroxetine. Am J Psychiatry. 1997 Apr; 154(4):543-6. PMID: 9090343.
    View in: PubMed
  105. Berman I, Sapers BL, Chang HH, Losonczy MF, Schmildler J, Green AI. Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine. J Clin Psychopharmacol. 1995 Jun; 15(3):206-10. PMID: 7635998.
    View in: PubMed
  106. Green AI, Schildkraut JJ. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harv Rev Psychiatry. 1995 May-Jun; 3(1):1-9. PMID: 9384923.
    View in: PubMed
  107. Berman I, Kalinowski A, Berman SM, Lengua J, Green AI. Obsessive and compulsive symptoms in chronic schizophrenia. Compr Psychiatry. 1995 Jan-Feb; 36(1):6-10. PMID: 7705089.
    View in: PubMed
  108. Green AI, Zalma A, Berman I, DuRand CJ, Salzman C. Clozapine following ECT: a two-step treatment. J Clin Psychiatry. 1994 Sep; 55(9):388-90. PMID: 7929018.
    View in: PubMed
  109. Albanese MJ, Khantzian EJ, Murphy SL, Green AI. Decreased substance use in chronically psychotic patients treated with clozapine. Am J Psychiatry. 1994 May; 151(5):780-1. PMID: 8166327.
    View in: PubMed
  110. Kahn M, Green AI. Psychosis, delirium, or both? Harv Rev Psychiatry. 1994 May-Jun; 2(1):34-8. PMID: 9384877.
    View in: PubMed
  111. Green AI, Alam MY, Boshes RA, Waternaux C, Pappalardo KM, Fitzgibbon ME, Tsuang MT, Schildkraut JJ. Haloperidol response and plasma catecholamines and their metabolites. Schizophr Res. 1993 Jun; 10(1):33-7. PMID: 8369230.
    View in: PubMed
  112. Green AI, Austin CP. Psychopathology of pancreatic cancer. A psychobiologic probe. Psychosomatics. 1993 May-Jun; 34(3):208-21. PMID: 8493302.
    View in: PubMed
  113. Seidman LJ, Pepple JR, Faraone SV, Kremen WS, Green AI, Brown WA, Tsuang MT. Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction. Biol Psychiatry. 1993 Apr 15-May 1; 33(8-9):575-84. PMID: 8101100.
    View in: PubMed
  114. Green AI, Alam MY, Sobieraj JT, Pappalardo KM, Waternaux C, Salzman C, Schatzberg AF, Schildkraut JJ. Clozapine response and plasma catecholamines and their metabolites. Psychiatry Res. 1993 Feb; 46(2):139-49. PMID: 8483973.
    View in: PubMed
  115. Holinger DP, Faux SF, Shenton ME, Sokol NS, Seidman LJ, Green AI, McCarley RW. Reversed temporal region asymmetries of P300 topography in left- and right-handed schizophrenic subjects. Electroencephalogr Clin Neurophysiol. 1992 Nov-Dec; 84(6):532-7. PMID: 1280199.
    View in: PubMed
  116. Berman I, Zalma A, DuRand CJ, Green AI. Clozapine-induced myoclonic jerks and drop attacks. J Clin Psychiatry. 1992 Sep; 53(9):329-30. PMID: 1517198.
    View in: PubMed
  117. Reich JH, Green AI. Effect of personality disorders on outcome of treatment. J Nerv Ment Dis. 1991 Feb; 179(2):74-82. PMID: 1990074.
    View in: PubMed
  118. Green AI, Faraone SV, Brown WA. Prolactin shifts after neuroleptic withdrawal. Psychiatry Res. 1990 Jun; 32(3):213-9. PMID: 1975101.
    View in: PubMed
  119. Green AI, Salzman C. Clozapine: benefits and risks. Hosp Community Psychiatry. 1990 Apr; 41(4):379-80. PMID: 2158938.
    View in: PubMed
  120. Faraone SV, Green AI, Brown W, Yin P, Tsuang MT. Neuroleptic dose reduction in persistently psychotic patients. Hosp Community Psychiatry. 1989 Nov; 40(11):1193-5. PMID: 2572532.
    View in: PubMed
  121. Green AI, Brown WA. Prolactin and neuroleptic drugs. Endocrinol Metab Clin North Am. 1988 Mar; 17(1):213-23. PMID: 2897910.
    View in: PubMed
  122. Green AI, Brown WA. Prolactin and neuroleptic drugs. Neurol Clin. 1988 Feb; 6(1):213-23. PMID: 2898095.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Green's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (349)
Explore
_
Co-Authors (27)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_